Chronic Central Serous Chorioretinopathy. Central serous chorioretinopathy
Conditions
Interventions
Intervention group: Patients in this group will be treated with 3 mg oral melatonin tablets (manufactured by Razak Laboratories) every 8 hours for 1 month..
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Chronic CSCR Lack of improvement in signs and symptoms of the disease at least 4 months after the incidence
Exclusion criteria
Exclusion criteria: History of Retinal MPC, PRP, or PDT History of intraocular injections of Anti-VEGF History of any ocular surgery other than an uneventful cataract surgery more than 6 months ago History of any other ocular disease such as uveitis, glaucoma, hypertensive retinopathy, diabetic retinopathy, CNV, or KCN Having visually significant cataracts Use of any immunomodulator medication such as corticosteroids Taking antioxidant medications such as vitamin E Use of any medication with adverse effects on the macula, such as Fingolimod and Deferoxamine Being under Chemotherapy History of any systemic condition needing medical treatment, such as an autoimmune disease Lack of consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central macular thickness. Timepoint: Before the intervention and 1 month after the intervention. Method of measurement: Macular Optical Coherence Tomography (OCT).;Best-corrected visual acuity. Timepoint: Before the intervention and 1 month after the intervention. Method of measurement: 6-meter E-Chart. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects. Timepoint: Weekly visits from the start of treatment until 1 month. Method of measurement: Physical examinations and History taking. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzam Alizadeh
Tabriz University of Medical Sciences
Outcome results
None listed